Study of aspirin effects on Permcath function in dialysis patients
Not Applicable
- Conditions
- Advanced renal failure.End stage renal disease
- Registration Number
- IRCT2013100114333N8
- Lead Sponsor
- Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 236
Inclusion Criteria
Patients who are allowed to receive aspirin, matched for age, sex, diabetes, cardiovascular disease and written informed consent.
Exclusion criteria: Patients who have coagulation disorders or use anticoagulant drugs, patients who are suffering from cancer or gastrointestinal bleeding
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Infection. Timepoint: Once a month for 6 months. Method of measurement: Based on physical examination, blood culture and discharge from permcath location.;Bleeding from Permcath location. Timepoint: Once a month for 6 months. Method of measurement: History and physical examination based on the initial amount of bleeding which doesn’t stop with primary cares and needs to surgical intervention.;Gastrointestinal bleeding. Timepoint: Once a month for 6 months. Method of measurement: blood in the stool or clinical signs such as bloody vomiting and abdominal pain.;Lifetime of Permcath. Timepoint: Once a month for 6 months. Method of measurement: Observing the patient’s record.
- Secondary Outcome Measures
Name Time Method